6634 ªYÄ£
ªÑ¥»: 3.832»õ
¥Dn·~°È:
¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo
¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)
¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)
Ä~Äò©¹¤U¬Ý...!
=============================================================================
²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)
¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.µL¦w¥þ©Ê°ÝÃD
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x
¬ãµo¶¥¬q:
1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á
2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ
Àø®Ä¤ÀªR¡G
1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n
2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)
=============================================================================
²£«~02¡GSNP-630
¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢
²£«~Àu¶Õ:
1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)
2.¥«³õº¨£·sÃÄ(First-in-class)
3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x
4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~
¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C
Ävª§¤O:
1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢
2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯×
3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡
4.µL¦w¥þ©Ê°ÝÃD
¬ãµo¶¥¬q:
1.Á{§É«e
2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C
3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C
Àø®Ä¤ÀªR¡G
1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05
=============================================================================
²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)
²£«~Àu¶Õ:
1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê
2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)
3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«
2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^
3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O
¬ãµo¶¥¬q:
1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç
2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D
3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç
=============================================================================
²£«~04¡GSNP-830/ SNP-840
¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh)
²£«~Àu¶Õ:
1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è
2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q
¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ
Ävª§¤O:
1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è
2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä
3.¦³¨Ï¥Î±M§Q¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y
4.¥i¼W¥[¤AñQÓi×ô¾¯¶q
¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î
5.¤GªÌ¾Ü¤@±ÂÅv
6.¥i¼W¥[¥«¦û²v
¬ãµo¶¥¬q:
1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç
SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç
µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ
=============================================================================
*****************************************************************************
SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G
1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005
=============================================================================
*****************************************************************************
¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G
1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv
3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv
=============================================================================
*****************************************************************************
¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º
§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó
¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄÆªÑ
-----------------------------------------------------------------------------
¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)
1.2005¦~11¤ë7¤é¡A¼Ú·ù©eû·|±Â¤©·ç¨åStricent AB¥Î©óªvÀøÅn©ÊÅÖºû¤Æªº¥ÌÅS¾Jªº©t¨àÃĺٸ¹¡]EU/3/05/325¡^¡C
¦Û 2012 ¦~ 4 ¤ë 13 ¤é°_¡A¥ÌÅS¾J¦b¼Ú·ù³Q±ÂÅv¬° ¤ä®ðºÞ¾J
¦b 2011 ¦~ 11 ¤ë 8 ¤é¦Ü 9 ¤éªº·|ij¤W¡A©t¨àÃÄ©eû·|( COMP ) ¼f¬d¤F±N Bronchitol¡]¥ÌÅS¾J¡A¥H«eºÙ¬°¥ÌÅS¿}
¾J¡^§@¬°ªvÀøÅn©ÊÅÖºû¤Æªº©t¨àÃĪº»{©wEU/3/ 05/325 ¡C
www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-05-325
2.2020.5.1-§l¤J¥ÌÅS¾JªvÀøÅn©ÊÅÖºû¤Æ
www.ncbi.nlm.nih.gov/pmc/articles/PMC7195814/
¥ÌÅS¾J¥i¼W¥[ÂH½¤ÅÖ¤ò²M°£²v¡A¦ý¨ä [½T¤Á§@¥Î¾÷Âà©|¤£²M·¡]¡C»P»Ýn³z¹L¼QÃú¾¹»¼°eªº²{¦³»s¾¯¬Û¤ñ¡A¥ÌÅS¾Jªº°®¯»»s
¾¯¥i¯à§ó¤è«K¥B§ó®e©ö¨Ï¥Î¡C§l¤J°®¯»¥ÌÅS¾JªvÀøÅn©ÊÅÖºû¤Æªº III ´Á¸ÕÅç¤w¸g§¹¦¨¡A²{¤w¦b¿D¬w©M¼Ú¬w¤@¨Ç°ê®a¤W¥«¡C
³o¬O¤§«eµû½×ªº§ó·s¡C
3.2020.11.2-Chiesi «Å¥¬ FDA §åã Bronchitol®¡]¥ÌÅS¾J¡^§l¤J¯»¥½
----------------------------------------------------------------------------------------------
µ¥«Ý¤fªA400mg¥ÌÅS¾J+400mg¤T´â½©¿}¦bMASH»P¿}§¿¯f¤j©ñ¥ú©ú!!!
2024.2.20-P©Rªº¯×ªÕ¡G¯ØÅ¦¤º¯×½è¾ÉP¯ØÅ¦Àù
¦b©s¼wº¸ÀH¾÷¤Æ©M«e¤©Ê¶¤¦C¬ã¨s¤¤¡A1¯ØÅ¦¤º¯×ªÕ·|¼W¥[¯ØÅ¦Àùªº·ÀI¡C³o¬°¯×½è»P¯ØÅ¦Àù¯g¤§¶¡ªº¦]ªGÃö«Y´£¨Ñ¤F¦³»¡ªA¤Oªº¤HÃþÃÒ¾Ú¡A[ÃÒ¹ê¤F¼ï¦·©Ô°²»¡ªº¹w´ú]¡C
---------------------------------------------------------------------------------------------------
¯ØÅ¦P©Rªº¯×ªÕ--2«¬¿}§¿¯f»P¡uÀù¤ý¡v¯ØÅ¦Àù
[©s¼wº¸ÀH¾÷¤Æ]³Q»{¬°Ãþ¦ü©ó¡u¦ÛµMªºÀH¾÷¹ï·Ó¸ÕÅç¡v---¦]ªGÃö«Y¬OÅKÃÒ¦p¤sµL¥iÅG»é!
³z¹L´î¤Ö¯ØÅ¦¯×ªÕ°fÂà²Ä 2 «¬¿}§¿¯f(¬ã¨s¤Hûªí©ú¡A³z¹L´îªÎ´î¤Ö¤£¨ì¤@§Jªº¯×ªÕ¥i¥H°fÂà¿}§¿¯f)
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/17 ¤U¤È 05:02:07²Ä 3830 ½g¦^À³
¥ÌÅS¾J+¤T´â½©¿}ªº¾÷¨î???
2024 ¦~ Rolf Luft ¼ú
-------------------------------------------------------------------------------------------------
SNP-6§¹³Æ2¦ì¿}§¿¯fÅv«Â»¡ªº°fÂà¾÷¨î!!!
¦]¨ä¹ï¿}§¿¯f¬ã¨sªº°^Äm¦ÓºaÀòMBE
2023.1.6- www.diabetes.org.uk/about-us/news-and-views/professor-roy-taylor-awarded-mbe-services-diabetes-research
--------------------------------------------------------------------------------------------------
¤@³õ½w¸Ñ²©R
®õ°Ç±Ð±Â«á¨Óªº¬ã¨s¶i¤@¨B´¦¥Ü¤F 2 «¬¿}§¿¯f¬O¦p¦óµo®iªº¡A¥H¤Î¦p¦óÅý¯ØÅ¦¦A¦¸¤u§@¥H¨Ï²Ä 2 «¬¿}§¿¯f½w¸Ñ¡C
¦Û 2008 ¦~¥H¨Ó¡A§Ṳ́@ª½¤ä«ù®õ°Ç±Ð±Âªº¶}³Ð©Ê½w¸Ñ¬ã¨s¡C¦ý®õ°Ç±Ð±Âªºµo²{§ï¼g¤F²Ä 2 «¬¿}§¿¯fªº¬G¨Æ¡C
¨ì 2011 ¦~¡A¥Lªº¬ã¨sµ²ªGªí©ú¡A¤@¨Ç 2 «¬¿}§¿¯f±wªÌ¥i¥H³z¹L§C¼ö¶q¶¼¹Å髺޲zpµe´î»´Åé«¡A±q¦ÓÀò±o½w¸Ñ¡C¥L¶}µo¤F³Ð·sªº¬ã¨s§Þ³N¡A³o·N¨ýµÛ§ÚÌ¥i¥H©çÄá¨xŦ©M¯ØÅ¦µ¥¾¹©x¤º³¡©M©P³òªº¯×ªÕ¤ô¥¹Ï¹³¡C
¥Lªº¥@¬Éº³Ðµ²ªGªí©ú¡A´î¤Ö¨xŦ©M¯ØÅ¦¤º¦h¾lªº¯×ªÕ¬O½w¸Ñ¯f±¡ªºÃöÁä¡C
¥Lªº¥@¬Éº³Ðµ²ªGªí©ú¡A´î¤Ö¨xŦ©M¯ØÅ¦¤º¦h¾lªº¯×ªÕ¬O½w¸Ñ¯f±¡ªºÃöÁä¡C
¥Lªº¥@¬Éº³Ðµ²ªGªí©ú¡A´î¤Ö¨xŦ©M¯ØÅ¦¤º¦h¾lªº¯×ªÕ¬O½w¸Ñ¯f±¡ªºÃöÁä¡C
40¤À:¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ
-----------------------------------------------------------------------------------------
³z¹L´î¤Ö¯ØÅ¦¯×ªÕ°fÂà²Ä 2 «¬¿}§¿¯f(¬ã¨s¤Hûªí©ú¡A³z¹L´îªÎ´î¤Ö¤£¨ì¤@§Jªº¯×ªÕ¥i¥H°fÂà¿}§¿¯f)
www.ncl.ac.uk/press/articles/archive/2015/12/pancreasstudy/
¥@¬É¿}§¿¯f¤j·|¤Wµoªí¡C¬ã¨sû®õ°Ç±Ð±Â(Professor Roy Taylor)¦b¤j·|¤W»¡¡G¡u²Ä¤G«¬¿}§¿¯f±wªÌ´î«¤§«á¡A¥i¥H´î¤Ö¯ØÅ¦ªº¦h¾l¯×ªÕ¡A«P¨Ï¯ØÅ¦¥\¯à«ì´_¥¿±`¡C¦]¦¹¡A¦pªG§A°Ý§Ú¡A¯f¤H»Ýn´î¤Ö´X¤½¤ç¤~¯à§ïµ½¿}§¿¯f¡Aµª®×´N¬O1¤½§J¡C¤£¹L¡A³o1¤½§J¥²¶·¬O¨Ó¦Û¯ØÅ¦ªº¯×ªÕ¡C¡v
Type 2 diabetes or pre-diabetes
Present, n=18 Not present, n=17
-----------------------------------------------------------------------------------------
§@ªÌ±o¥Xµ²½×¡A¨xŦ¯×ªÕ°ï¿n¥i¯à¬OÂà¤Æ¬°¿}§¿¯fªºÄ²µo¨Æ¥ó¡C¬°¤F¤ä«ù«á¤@ºØ¥i¯à©Ê¡A¤w¸gµo²{[ALT¤É°ª]¬Oµo¥Í 2 «¬¿}§¿¯fªº¦´Á¦MÀI¦]¯À¡A»PªÎD¡BÅé¯×ªÕ¤À§G¡B¦å¿}¡B¦å¯×¡BAST¡BÁx¬õ¯À¿@«×©M®a±Ú¥vµLÃö....
-----------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/18 ¤U¤È 11:23:36²Ä 3841 ½g¦^À³
www.sinewpharma.com/Upload/202312/news_2023122509345208.pdf
Type 2 diabetes or pre-diabetes
Present, n=18 Not present, n=17
......Also exploring a case study of this in a phase 2 [oral insulin] versus placebo study?
[oral insulin]¤fªA¯Ø®q¯À¡A¿}§¿¯f???
2«¬¿}§¿¯f©MNAFLD ±wªÌªº[ALT¤U°]»P [¨xŦ¯×ªÕ´î¤Ö] ¦³Ãö....(SNP-610°§C29.5 U/L)
2«¬¿}§¿¯f©MNAFLD ±wªÌªº[ALT¤U°]»P [¨xŦ¯×ªÕ´î¤Ö] ¦³Ãö....(SNP-610°§C29.5 U/L)
2«¬¿}§¿¯f©MNAFLD ±wªÌªº[ALT¤U°]»P [¨xŦ¯×ªÕ´î¤Ö] ¦³Ãö....(SNP-610°§C29.5 U/L)
-----------------------------------------------------------------------------------------------
1. 2024.5.17-[2«¬¿}§¿¯fªºªvÀø¼Ò¦¡¬O®ÉÔÂàÅܤF]
www.mdpi.com/1422-0067/25/10/5488#B55-ijms-25-05488
....³oªí©ú²Ä2«¬¿}§¿¯f¡]¥Dn¡^¬O¥Ñ¨xŦ©M¯ØÅ¦¤º¹L¦hªº¯×ªÕ¤Þ°_ªº¡C
....¦]¦¹¡A¦´Á¹w¨¾/´î¤Ö[¨xŦ]©M[¯ØÅ¦]²§¦ì¯×ªÕ°ï¿n¥i¯à¦¨¬°²Ä¤G«¬¿}§¿¯fºÞ²zªº¥DnªvÀø¥Ø¼Ð¡C
2.2008.8.26- 2«¬¿}§¿¯fªºµo¯f¾÷Âà¡G°lÂܱqªv¡¨ì¯f¦]ªº¤Ï¦V¸ô®|
link.springer.com/article/10.1007/s00125-008-1116-7
¨xŦ©M¯Ø®q¤¤ªº[²§¦ì¯×ªÕ¨I¿n]¬O¨xŦ¯Ø®q¯À§Ü©Ê©M [£]²ÓM¥\¯à»Ùê]¬ÛÃö°ÊºA¯Ê³´ªº°ò¦¡C³o¨Ç¯Ê³´¦b§C¯à¶qÁý¾i±ø¥ó¤U¯à°÷ÅãµÛ°fÂà¡A¦b¦´Á¿}§¿¯f¤¤§¹¥þ°fÂà¡A
--------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/11/23 ¤U¤È 09:34:59²Ä 3543 ½g¦^À³
ALT °§C¶W¹L 17 U/L ¤w³QÃÒ©ú»P NASH ±wªÌªº²Õ´¾Ç¤ÏÀ³¬ÛÃö(ÅÖºû¤Æ§ïµ½)!-->SNP-610°§C29.5 U/L.
www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/
¶ø¨©Áx»Ä( InterceptªºOCA)¡B elafibranor©M§Q©Ô¾|肽(¿Õ©M¿Õ¼w)ªº¬ã¨s¤wÃÒ©ú¡A¦bNASHªvÀø¬ÛÃö²Õ´¾Ç§ïµ½©Î®ø°hªº±wªÌ¤¤¡AALT ·|¤U°¡A¦Ó¥B2«¬¿}§¿¯f©MNAFLD ±wªÌªºALT ¤U°»P¨xŦ¯×ªÕ´î¤Ö¦³Ãö....
SNP-810µLµÇ¬r©Ê³oÓÀuÂI¡A¹ï©ó·m§ðNSAIDs¡]«DÃþ©T¾J®øª¢¤îµhÃÄ¡^ªº¥«³õ¥÷ÃB¤j¦³§U¤O!
¤îµhÃį}ÃaµÇŦ«OÅ@¾÷¨î!!!
www.commonhealth.com.tw/article/74087
½Ð·V¥Î¤îµhÃÄ¡IµÇŦ¬ì¦WÂå¨Iµh§i¥Õ
------------------------------------------------------------------------------------------------
2024.7.2-¼³¼ö®§µh¹L¶q¾ÉP«æ©Ê[µÇ] ·l¶Ë¦ý[µL¨x¬r©Ê]¡G¯f¨Ò³ø§i
intjem.biomedcentral.com/articles/10.1186/s12245-024-00662-w
µ²½×
Á`¤§¡A¼³¼ö®§µh [µÇ¬r©Ê] ¦Ó [¤£¨x¬r©Ê]¨Ã¤£¨u¨£¡A¥BÀ³ºÊ´ú±wªÌ¶W¹L 48 ¦Ü 72 ¤p®É¡C¾¨ºÞ NAC ¦b¨x¬r©Ê¤è±ªº§@¥Î²³©Ò©Pª¾¡A¦ý¨ä¦b¹w¨¾µÇ¬r©Ê¤è±ªº§@¥Î©|¥¼±o¨ìÃÒ¹ê¡C
40¤À:¤îµhÃÄ(«D³B¤èÃÄ)µ¦²¤©Ê¼Ú¬ü¤À¶}±ÂÅv
--------------------------------------------------------------------------
¬°¦ó¤À¶}±ÂÅv?
¥i¯à»P³o¦³Ãö«Y:2023.7.28www.gao.gov/assets/gao-23-106570.pdf ¬ü°êFDA[«D³B¤èÃÄ]¤¤±Æ¥L©Ê±ø´Ú(¥«³õ¿W¦ûÅv)
2024.6.21-½ä¿ùÃä¡I¥x¿n¹q¡u¹H¬ù¥æ³Î2892¸U¡v¡@ºÃ¤Ö¦~ªÑ¯«¤@¤i½ß¥ú
-------------------------------------------------------------------------------
¦~»´¤H²×¨s¬O¦~»´¤H¡A¤Ó½Ä°Ê¤F¡CªÅ¤û®ð¨R¤Ñªº¥xG?
¤£¹L¦~»´¤]¬O¥»¿ú¡A¯d±o«C¤s¦b¤£©È¨S®ã¿N¡A§O§Ñ±Ð°V´N¦n~
....º¡¤j¾÷²v´N¯à¤W¨ì³Ì³»¼h ¡A¦]¦¹(§Ú)Ä~Äò«ù¦³...
--------------------------------------------------------------------------------
...·ç»È¶°¤½¥¬ªº¾ÚÅã¥Ü¡A²b¸ê²£¦b300¸U¨ì3000¸U·s¥x¹ôªº¡u·Ç´I¸Î¼h960¸U¤H¡v¡A¥e¥þ¥x¤H¤f45%¡A±Nªñ¤@¥b...
-------------------------------------------------------------------------------------------------
Ó¤Hµ²½×:P´I¤§¹D¡A§Ö´N¬OºC¡AºC´N¬O§Ö¡C(«ùªÑ>12¦~)
...¼B³Ó«iµªÂЪí¥Ü....PȥثeÁÙ¥¼®³¨ì....©Ò¥HµLªk¤½¥¬¡C
¬O¯uª÷´N¤£©È¤õ·Ò¡A¤p´²¤á¤j©È¬Æ? ©ú¤ÑÃöt£x.
------------------------------------------------------------------------------------------------
§Ú¬J¬ÝªÅ´N¤£°µ¦h¤]¤£°µªÅ¡A°O¤£²M¬O¨º¦~¼o¤F¿Ä¸ê¨é¸ê®æ¡C
P´I¤§¹D¡A§Ö´N¬OºC¡AºC´N¬O§Ö¡A[°í«ù¦Û§Ú§PÂ_]¡A±E±x¦Û¤vªº§ë¸ê¸`«µ!
P´I¤§¹D¡A§Ö´N¬OºC¡AºC´N¬O§Ö¡AµLÄߪi°Ê¡A[°í«ù¦Û§Ú§PÂ_]
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/13 ¤U¤È 05:27:50²Ä 3807 ½g¦^À³
¦p¦ó°í¦u¤º¤ßªº¡§§ë¸ê¸`«µ¡¨¡H
ªÑ»ù¤Wº¦®É¿³¾Ä¡A§Ô¤£¦í·Qn¥[Ü¡F¤U¶^®É¤S¼~¼{¡A§Ô¤£¦í¤S»°ºò³Î¦×¡A¸¨³U爲¦w¡A©ó¬O¤@º¦´N¶R¡A¤@¶^´N½æªº¦æ爲µL´`Àô!
¬Ý¬O¤£¬O¦pJp»¡ªº³o¦n¡A¶R¤F©ñµÛ¤~¦³«H¤ß
Â಴Q3n¨ì¤F¡A³oÀɯu¬O¿\¥ÉÁÙ¬O¥ÛÀY?
¥H²{¦bÃĪ«¤W¥«¼f¬dì«h¡AAPAP¬O¤£¥i¯à¦b¬ü°ê»P^°ê¤W¥«¡C
SNP-810µL¨x¬r·s¾¯«¬·sÃÄ¥¿¬O³Ð·s¦w¥þ§ï²¡A¯àÀò±o¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n¤°»ò¿EÀy¹ªÀy???????
2020¦~3¤ë27¤é¤t´¶Ã±¸pªº¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n´N¬On¸Ñ¨M³oÃþÃĪ«ªº°ÝÃD¡C
-----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/4 ¤U¤È 05:35:26²Ä 461 ½g¦^À³
1972¦~FDA¥l¶°¤F¤@²ÕÂå¥Í©M¬ì¾Ç®a¨Óµû¦ô¤îµhÃÄ(¥]¬A¹ï¤A酰®ò°ò×ô)..µ²ªGªá¤F48¦~©|¥¼¸Ñ¨M¨x¬r©Ê¡C Orz.
1. 2012¦~1¤ë24¤é
---FDA¤µ¤Ñ¤£·|§å...¹ï¤A酰®ò°ò×ô(APAP)¤]¬O¤@¼Ë¤£·|§åã¡]¦b¬ü°ê¡A¹L¶q¨Ï¥Î¬O¾ÉP¨x°IºÜªº¥Dnì¦]¡^
Analgesics have a spotty history of switching to OTC. According to common wisdom, the FDA would not approve aspirin today much less allow it to go OTC. The same could be said for acetaminophen (overdose of which is the leading cause of liver failure in the US)
---------------------------------------------------------------------------------------------
¥H²{¦bFDAÃĪ«©Ê¨x·l¶Ë¤W¥««eÁ{§É«ü«n¡AAPAP¹L¤£¤F¨x¬r©ÊªùÂe!
ÃĪ«¨x·l¶Ë«ü«n¤@Åé¾A¥Î!
FDAÃĪ«©Ê¨x·l¶Ë¤W¥««eÁ{§Éµû¦ô¦æ·~«ü«n
www.fda.gov/media/116737/download
------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/7/4 ¤W¤È 07:26:47²Ä 3875 ½g¦^À³
1.2024.4.15-¥[¤J £] ²ÓM¨ë¿EªvÀø[²Ä1«¬]¿}§¿¯fªº¸ÕÅç
¤@¶µ¸ÕÅ祿¦b©Û¶Ò±w¦³²Ä 1 «¬¿}§¿¯fªº¦¨¦~¤H¨Ó¬ã¨s BMF-219¡A³o¬O¤@
2.2024.6.7-FDA ¹ï Biomea Fusion ªº BMF-219 ¿}§¿¯f¸ÕÅç¶i¦æ¥þ±Á{§ÉÀÁ¸m
¸Ó¨M©w¬O°ò©ó COVALENT-111 ¸ÕÅ礤µo²{ªº¼ç¦bÃĪ«¤Þ°_ªº[¨x¬r©Ê]¤ô¥¡C
----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/1 ¤U¤È 01:00:55²Ä 3748 ½g¦^À³
µL¨x¬rSNP-810(12g) VS. ¦³¨x¬rAPAP(4g)ªº[¾î¦V¤ñ¸û]:
4.FDA Drug Hepatotoxicity Steering Committee:
.....(ALT) ≥3 times the upper limit of normal (ULN) and ALT/alkaline phosphatase (ALP) ratio ≥5 times ULN; cholestatic DILI by an ALP ≥2 times ULN and ALT/ALP ratio of ≤2 times ULN; and mixed DILI with ALT ≥3 times ULN, ALP ≥2 times ULN and ALT/ALP ratio <5 but >2 times ULN
¨x·l®`¤@¯ë©w¸q«üALT¶W¹L¥¿±`數ȤWªº3¿¥H¤W¡A§Y¶W¹L>3¿³q±`³Q»{¬°¨ã¦³Á{§É·N¸q¡C
2.¤T´â½©¿}[§í¨îCD4+ CD8+ T ²ÓM¼W´Þ]
쥻§ë¸êªYÄ£ªºÃöª`ÂI¡AÀ£®Ú¨S¬ÝªvÀø¿}§¿¯f³o¶ô¡A¤µ¤Ñ¯u¬O¡m¬ü¦nªº·N¥~¡n¡C
--------------------------------------------------------------------------------------------------
2024.9.24-²Ä¤K©¡ªi¤h¹yMASHÃĪ«¶}µo°ª®p·|-¦¶¸³¤fÀY³ø§i:
......Also exploring a case study of this in a phase 2 [oral insulin] versus placebo study?
[oral insulin]¤fªA¯Ø®q¯À¡A¿}§¿¯f???
°ª¿@«×ªº¤T´â½©¿}¥i¯à¾ÉPPLC-£^1»P(¬¡¤Æªº¡^T²ÓM¨üÅ骺ªÅ¶¡¶ZÂ÷§ó¤j¡A±q¦Ó¤¤Â_°T¸¹¶Ç¿é¡A[§í¨îCD4+ CD8+ T ²ÓM¼W´Þ]
2017.8.1-[1«¬¿}§¿¯f]¤¤ªº¦Û¨¤ÏÀ³©Ê T ²ÓM www.jci.org/articles/view/94549
§Ú̹ï¤HÃþT1Dªº²z¸Ñ¤¤¡A[£]²ÓM]ªº¯}Ãa¥Dn¬O¥Ñ§K¬Ì¤ÏÀ³ªº¾AÀ³©ÊÁuªº[CD4 +©MCD8 + T²ÓM] ÅX°Êªº§K¬Ì§ðÀ»¤Þ°_ªº
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/24 ¤U¤È 06:33:18²Ä 3850 ½g¦^À³
¦A¬Ý¤@¦¸¥h¦~ªº[1«¬¿}§¿¯f]ªº¹Ú¦³¦h¤j!
40¤À:¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ
µ²½×:±q¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ¡A8¦¨´N¬O¦³ÅãµÛ¼Æ¾Ú¬°¨Ì¾Ú!
----------------------------------------------------------------------------------------------
2011.6.9--2«¬¿}§¿¯fªº°fÂà¡G£] ²ÓM¥\¯à¥¿±`¤Æ»P¯ØÅ¦©M¨xŦ¤T»Ä¥Ìªoà´î¤Ö¦³Ãö
link.springer.com/article/10.1007/s00125-011-2204-7
¥Ø«eªº¼Æ¾Ú´£¨Ñ¤F©ú½TªºÃÒ¾Ú¡A
Åã¥Ü¯ØÅ¦Á`¯×ªÕªº´î¤Ö»P[£]²ÓM¥\¯àªº«ì´_]¦³Ãö¡C
Åã¥Ü¯ØÅ¦Á`¯×ªÕªº´î¤Ö»P[£]²ÓM¥\¯àªº«ì´_]¦³Ãö¡C
Åã¥Ü¯ØÅ¦Á`¯×ªÕªº´î¤Ö»P[£]²ÓM¥\¯àªº«ì´_]¦³Ãö¡C
¦Ó«¤¤¤§«©Î³\¦bT1R3 ¯Ê¥¢-->[Âù¬Û]¯Ø®q¯À¤Àªc¨ü¨ìÅãµÛ§í¨î!!!
------------------------------------------------------------------------------------
2024.1.26--¥\¯à²§½è©Ê£]²ÓM½Õ¸` [Âù¬Û] [Âù¬Û] [Âù¬Û]¯Ø®q¯À¤Àªc
www.nature.com/articles/s42255-023-00964-y
...§Ú̶i¤@¨Bªí©ú¡ARR£]s ªº¥\¯à»Ùê¦b¿}§¿¯fªº¶i®i¤¤°_µÛ¦ÜÃö«nªº§@¥Î¡C
2017.9.17-[¸²µå¿}±Ó·P¨üÅé] ¦b¯Ø®q¯À¤Àªc¤¤ªº§@¥Î
µL½×¦p¦ó
T1R3 ªºªí¹F¦bªÎD©M¿}§¿¯f¤¤[°§C]¡C½T©w¦b¤HÃþªÎD©Î¿}§¿¯f¤¤¬O§_Æ[¹î¨ìÃþ¦üªºªí¹FÅܤƱN¬O«Ü¦³½ìªº¡C
---------------------------------------------------------------------------------------------
2005.3.1-«C¤Ö¦~²Ä 2 «¬¿}§¿¯f¡G¯Ø®q¯À§Ü©Ê¡B£] ²ÓM°IºÜ¡A©Î¨âªÌݨã¡H
diabetesjournals.org/care/article/28/3/638/27718/Youth-Type-2-DiabetesInsulin-resistance-cell
µ²½×
³o¬O²Ä¤@¶µ°w¹ï«C¤Ö¦~ªº¬ã¨s¡AÅã¥Ü»P¬Û¤Ç°tªºªÎD¹ï·Ó¨ü¸ÕªÌ¬Û¤ñ¡A±w¦³²Ä 2 «¬¿}§¿¯fªº«C¤Ö¦~ªº¯Ø®q¯À±Ó·P©Ê©M¯Ø®q¯À¤Àªc§¡¨ü·l...¦ý¥O¤H¤£¦wªºÆ[¹îµ²ªG¬O¦b«Ü¤pªº®Éԯخq¯À¤Àªc´NÄY«¨ü·l¡]FPIS °§C¬ù75%¡FSPIS °§C¬ù50 %¡^¿}§¿¯f¯fµ{¬Û¹ï¸ûµu¡C³o¨Çµo²{ªº·N¸q¥i¯à¬O¦´Á»Ýn¯Ø®q¯À´À¥NÀøªk¨Óºû«ù¦å¿}±±¨î¡C
Ó¤Hµ²½×:2005¦~¡]FPIS °§C¬ù75%¡FSPIS °§C¬ù50 %¡^?µª®×À³¸Ó¬O2017¦~£]²ÓMªºT1R3¯Ê¥¢(FPIS»PSPIS³£¨ü¨ìÅãµÛ§í¨î!!!)
¦A¬Ý¤@¦¸¦P¦æªº(¤T´â½©¿}T1R3¿E¬¡¾¯)¬ã¨s:
1.2024.5.21-¤G¤Q¦~¬ã¨s¡G²¢¨ý¨üÊ^¼v响¤HÊ^¥N谢¸²µå¿}ªº¤è¦¡
¥L们发现¡A将TAS1R2-TAS1R3¿E动剂(¤T´â½©¿})
2.Nature¥D¥Z¿¯¹²¢¨ý¾¯[¤T´â½©¿}]¬O T ²ÓM¤¶¾É¤ÏÀ³ªºt½Õ¸`¾¯
3.2.¤T´â½©¿}³Q½T©w¬°¯Ø¸¢£]²ÓM©MT1R3²¢¨ý¨üÅ骺¿E¬¡¾¯
www.e-enm.org/journal/view.php?doi=10.3803/EnM.2014.29.1.12
4..........
5..........
§ó«nªº¬O¡A¦b [T1R3¯Ê¥¢] [T1R3¯Ê¥¢] [T1R3¯Ê¥¢]ªº¯Ø®q¤¤¡A
¯Ø®q¯À¤Àªcªº¨âÓ¶¥¬q: ²Ä¤@¬Û¯Ø®q¯ÀÄÀ©ñ(FPIS)»P²Ä¤G¬Û¯Ø®q¯ÀÄÀ©ñ(SPIS)³£¨ü¨ì[ÅãµÛ§í¨î]!!!
³Ì¨Î¦å¿}±±¨î»Ýn²Ä¤@¬Û©M²Ä¤G¬Û¯Ø®q¯ÀÄÀ©ñ¡C
³Ì¨Î¦å¿}±±¨î»Ýn²Ä¤@¬Û©M²Ä¤G¬Û¯Ø®q¯ÀÄÀ©ñ¡C
³Ì¨Î¦å¿}±±¨î»Ýn²Ä¤@¬Û©M²Ä¤G¬Û¯Ø®q¯ÀÄÀ©ñ¡C
FPISÄÀ©ñ¹ï©ó¹ï§Ü¤É¿}¯À¹ï¸²µå¿}²£¥Íªº [§Ö³t] ¼vÅT«Ü«n¡A¦ÓSPISÄÀ©ñ¹ï©ó [ºû«ù] ³oºØ§í¨î¨Ã¼W¥[¸²µå¿}§Q¥Î²v«Ü
«n¡C¯Ê¥FFPISÄÀ©ñ·|¾ÉPµu¼È¡]2¤p®É¡^©M¤¤«×¡]20-30 mg/dl¡^¦å¿}¯Ê³´¡A¦Ó¯Ê¥FSPISÄÀ©ñ·|¾ÉPªø´Á¥B¼@¯P¡]70-100
mg/dl¡^¦å¿}¯Ê³´¡C
------------------------------------------------------------------------------------------------
1.2024.1.26--¥\¯à²§½è©Ê£]²ÓM½Õ¸` [Âù¬Û] [Âù¬Û] [Âù¬Û]¯Ø®q¯À¤Àªc
www.nature.com/articles/s42255-023-00964-y
µo²{©ö©óÄÀ©ñªº £] ²ÓM¡]RR£]¡^¬O¹ïÂù¬Û¸²µå¿}¨ë¿Eªº¯Ø®q¯À¤Àªc¦³¤£¦¨¤ñ¨Ò°^Ämªº¨È¸s¡C§Ú̶i¤@¨Bªí©ú¡ARR£]s ªº¥\¯à»Ùê¦b¿}§¿¯fªº¶i®i¤¤°_µÛ¦ÜÃö«nªº§@¥Î¡C
2.2023.2.27-²Ä¤@¬Û¯Ø®q¯À¤Àªc¡G¨äµû¦ô¯à§_«ü¾ÉªvÀø¤èªk¡H
www.sciencedirect.com/science/article/pii/S1043276023000309
...§ÚÌ®i¥Ü¤F²Ä¤@¬Û¯Ø®q¯À¤Àªc»P¸²µå¿}úAªº¬ÛÃö©Ê¡A¨Ã¤ÀªR¤F¨ä´î¤Ö¹ïÁ{§Éªí²{¡]¯S§O¬OÀ\«á°ª¦å¿}¡^©M¯e¯fµ²ªGªº
¼vÅT¡C¦b³oºØ±¡ªp¤U¡A«ì´_ £] ²ÓM¥\¯à¥i¯à·|¦¨¬°¹w¨¾©MªvÀø¿}§¿¯fªº¹CÀ¸³W«h§ïÅܪÌ
¦b³oºØ±¡ªp¤U¡A«ì´_ £] ²ÓM¥\¯à¥i¯à·|¦¨¬°¹w¨¾©MªvÀø¿}§¿¯fªº¹CÀ¸³W«h§ïÅܪÌ
¦b³oºØ±¡ªp¤U¡A«ì´_ £] ²ÓM¥\¯à¥i¯à·|¦¨¬°¹w¨¾©MªvÀø¿}§¿¯fªº¹CÀ¸³W«h§ïÅܪ̡A
dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.13013
³o¨Çµ²ªGªí©ú[T1R3©MCaSR]ªº²§¤G»EÅé¬O [¸²µå¿}±Ó·P¨üÅé]ªº¥Dn¦¨¤À¡C
...
·í´ú¶q±q T1R3 ºV°£¤p¹«Àò±oªº¯Ø®q¤¤ªº¯Ø®q¯À¤Àªc®É¡A»P¥¿±`¤p¹«ªº¯Ø®q¬Û¤ñ¡A¸²µå¿}»¤¾Éªº¯Ø®q¯À¤Àªc³Q§í¨î¬ù 40%¡C§ó«nªº¬O¡A¦bT1R3¯Ê¥¢ªº¯Ø®q¤¤¡A¯Ø®q¯À¤Àªcªº²Ä¤@¶¥¬q©M²Ä¤G¶¥¬q³£¨ü¨ìÅãµÛ§í¨î
..µL½×¦p¦ó
T1R3 ªºªí¹F¦bªÎD©M¿}§¿¯f¤¤[°§C]¡C½T©w¦b¤HÃþªÎD©Î¿}§¿¯f¤¤¬O§_Æ[¹î¨ìÃþ¦üªºªí¹FÅܤƱN¬O«Ü¦³½ìªº¡C
T1R3 ªºªí¹F¦bªÎD©M¿}§¿¯f¤¤[°§C]¡C½T©w¦b¤HÃþªÎD©Î¿}§¿¯f¤¤¬O§_Æ[¹î¨ìÃþ¦üªºªí¹FÅܤƱN¬O«Ü¦³½ìªº¡C
T1R3 ªºªí¹F¦bªÎD©M¿}§¿¯f¤¤[°§C]¡C½T©w¦b¤HÃþªÎD©Î¿}§¿¯f¤¤¬O§_Æ[¹î¨ìÃþ¦üªºªí¹FÅܤƱN¬O«Ü¦³½ìªº¡C
-----------------------------------------------------------------------------------------
(¤T´â½©¿}³Q½T©w¬°[¯Ø¸¢£]²ÓM] ©MT1R3²¢¨ý¨üÅ骺¿E¬¡¾¯)
2024.9.24-²Ä¤K©¡ªi¤h¹yMASHÃĪ«¶}µo°ª®p·|-¦¶¸³¤fÀY³ø§i:
......Also exploring a case study of this in a phase 2 [oral insulin] versus placebo study?
À³¸Ó«Ü¦³½ìªº!
(¤T´â½©¿}³Q½T©w¬°[¯Ø¸¢£]²ÓM] ©MT1R3²¢¨ý¨üÅ骺¿E¬¡¾¯)
1.2024.5.21-¤G¤Q¦~¬ã¨s¡G²¢¨ý¨üÊ^¼v响¤HÊ^¥N谢¸²µå¿}ªº¤è¦¡
m.ebiotrade.com/newsf/2024-5/20240518052435596.htm
¥L们发现¡A将TAS1R2-TAS1R3¿E动剂(¤T´â½©¿}¡A¤@Ïú¹s热¶q²¢¨ý剂)©ÎTAS1R2-TAS1R3«ú§Ü剂(¨Å»Äà¡A¤@Ïú§í¨î²¢¨ýªº钠盐)ÉO¸²µå¿}²V¦X¡A会¥H¤£¦Pªº¤è¦¡剧¯P§ï变¤HÊ^ªº¸²µå¿}@¶q¡C
¤@个¤Hªº°·±d状úGÉO¨äTAS1R2-TAS1R3¨üÊ^ªº¬¡©Ê¤§间¬O§_¦s¦b关¨t?该¬ã¨sªº§@ªÌ说¡A¡§¥i¯à¡¨¡A这ªí©ú¨üÊ^¿E¬¡ªºµ{«×对¦å¿}©M¯Ø岛¯À¤ô¥¤Î¨ä发¯f时间¦³严«¼v响¡A这对¥N谢°·±d«Ü«n¡C
2.2024.5.18-¿}§¿¯f¡A¦Þ¦y¤Wªºªv·U¡C²¢¨ý¨üÊ^¬O关键吗¡H
zh-cn.futuroprossimo.it/2024/05/diabete-la-cura-sulla-punta-della-lingua-la-chiave-e-il-recettore-del-dolce/
1.2024.3.20-¿}§¿¯f¤¤±w¯fªº £] ²ÓM¡G«æ¶E«Ç¤§®Èªº¨£¸Ñ¡G2023 ¦~³Ç¥X¬ì¾Ç¦¨´N¼úÁ¿®y
2.2009¦~-¯ØÅ¦ £] ²ÓM¤¤ªí¹Fªº²¢¨ý¨üÅé·|¬¡¤Æ¶t©MÀô AMP °T¸¹¨t²Î¨Ã¨ë¿E¯Ø®q¯À¤Àªc
journals.plos.org/plosone/article?id=10.1371/journal.pone.0005106
¤T´â½©¿}¹ï [Ca 2+ ] c©M [cAMP] cªº¼vÅT¡C
-----------------------------------------------------------------------------------
2½g¬ã¨s°Â¦b¤@¶ô¡A·Q¤@¤USNP-6(¥ÌÅS¾J+¤T´â½©¿})ªºÃIJz¾÷¨î???
¤@¶µ¸ÕÅ祿¦b©Û¶Ò±w¦³²Ä 1 «¬¿}§¿¯fªº¦¨¦~¤H¨Ó¬ã¨s BMF-219¡A³o¬O¤@ºØ¨ë¿E £] ²ÓM¥Íªøªº·s«¬¤fªAÃĪ«¡C¸ÓÃĪ«¤w¦b
[²Ä2«¬]¿}§¿¯fªvÀø¤¤Åã¥Ü¥X¥i³ßªº®ÄªG¡A¥i§ïµ½½d³ò®É¶¡©M¦å¿}±±¨î¡C
2.2024.6.7-FDA ¹ï Biomea Fusion ªº BMF-219 ¿}§¿¯f¸ÕÅç¶i¦æ¥þ±Á{§ÉÀÁ¸m
¸Ó¨M©w¬O°ò©ó COVALENT-111 ¸ÕÅ礤µo²{ªº¼ç¦bÃĪ«¤Þ°_ªº[¨x¬r©Ê]¤ô¥¡C
------------------------------------------------------------------------------------------
¤p¤À¤lÃÄ¥\¯à©Êªv¡1«¬»P2«¬¿}§¿¯fªºÁ{§É¸ÕÅç¡Aº§å2¦W1«¬¿}§¿¯f±wªÌ£]细M¥\¯à±o¨ì§ïµ½¡A¦³®Ä¦ý¦]¬°[¨x¬r©Ê]À³¸Ó¬O¨SÀ¸¤F!
......Also exploring a case study of this in a phase 2 [oral insulin] versus placebo study?
-------------------------------------------------------------------------------------------------
www.sinewpharma.com/Upload/download/20240606-video.MP4
40¤À:¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ
µ²½×:±q¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ¡A8¦¨´N¬O¦³ÅãµÛ¼Æ¾Ú¬°¨Ì¾Ú!
......Also exploring a case study of this in a phase 2 [oral insulin] versus placebo study?
[oral insulin]¤fªA¯Ø®q¯À¡A¿}§¿¯f???
-----------------------------------------------------------------------------------------------
[oral insulin]¤fªA¯Ø®q¯À--->¿}§¿¯f·s[¶t]©À???
ª`·N¤£¬O²ÓM»P°Êª«¹êÅç¡A¦Ó¬O¤HÅéÁ{§É¸ÕÅç¼Æ¾Ú!!!
www.sciencedirect.com/science/article/pii/S2090123223003120
-----------------------------------------------------------------------------------------
¤T´â½©¿}³Q½T©w¬°[¯Ø¸¢£]²ÓM] ©MT1R3²¢¨ý¨üÅ骺¿E¬¡¾¯
2024.3.20-¿}§¿¯f¤¤±w¯fªº £] ²ÓM¡G«æ¶E«Ç¤§®Èªº¨£¸Ñ¡G2023 ¦~³Ç¥X¬ì¾Ç¦¨´N¼úÁ¿®y
diabetesjournals.org/diabetes/article/73/4/545/154111/The-Ailing-Cell-in-Diabetes-Insights-
From-a-Trip
²§±`ªº[£]²ÓM] [¶t] °T¸¹¶Ç¾É¾ÉP T1D µo¯f¾÷¨î.......
¥O¤HÅå³Yªº¬O¡A¶tªº´î¤Ö»PÅãµÛªº¤º½èºôÀ£¤Oªí«¬µLÃö¡A¦Ó¬O¾ÉP[¤º½èºô¶t]ªºÅܤơA¾ÉP[²É½uÅé¶t]¤ô¥¤É°ª©M²É½uÅé¥\¯à»Ùê¡A³Ì²×¥[³t¿}§¿¯fªºµo¯f¡C
-------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/12 ¤U¤È 05:09:10²Ä 3805 ½g¦^À³
2023.7.27-²ÓM¤º[¶t]°T¸¹¶Ç¾É¡G±`¨£¶ûºÃ¤Hªº·N·Q¤£¨ìªº[·s¨¤¦â]!!!
www.ncbi.nlm.nih.gov/pmc/articles/PMC10413985/
...§ïÅܲÓM¾¹¶¡ Ca 2+³q¶qªº·L§®¥¿Å¥i¯à¾ÉP¦M¤Î¥Í©Rªº¯e¯f¡A¨Ò¦pAD¡BÀù¯g©M·»酶Åé¶J¿n¯g¡A¨Ã¥B¦b¥¼¨Ó¥i¯à·|µo²{§ó¦h¯e¯f...
-------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/2 ¤W¤È 09:22:24²Ä 3751 ½g¦^À³
¥ÌÅS¾J(¶t/Áâ§l¦¬«O¯d)+¤T´â½©¿}(T1R3¿E°Ê¶tÁâ)¡u¤@¥[¤@¤j©ó¤G¡vªº®ÄÀ³!ªºÅܤơC
----------------------------------------------------------------------------------
Nature¥D¥Z(¿¯¹²¢¨ý¾¯¤T´â½©¿}¬O T ²ÓM¤¶¾É¤ÏÀ³ªºt½Õ¸`¾¯--(¤T´â½©¿}´î¤Ö¤FT²ÓM¤¤TCR¨Ì¿à©Ê¶t³q¶q¡A¦Ó¤£§ïÅܾãÅé²ÓM¤º¶tÀx¦s)
www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00051-X
¦b©s¼wº¸ÀH¾÷¤Æ©M«e¤©Ê¶¤¦C¬ã¨s¤¤¡A1¯ØÅ¦¤º¯×ªÕ·|¼W¥[¯ØÅ¦Àùªº·ÀI¡C³o¬°¯×½è»P¯ØÅ¦Àù¯g¤§¶¡ªº¦]ªGÃö«Y´£¨Ñ¤F¦³»¡ªA¤Oªº¤HÃþÃÒ¾Ú¡A[ÃÒ¹ê¤F¼ï¦·©Ô°²»¡ªº¹w´ú]¡C
[ÃÒ¹ê¤F¼ï¦·©Ô°²»¡ªº¹w´ú]
40¤À:¶}µoªvÀø¯×ªÕ[¯Ø]·s¥Î³~·sÃÄ
°ê»Ú3¤j³»¥ZCNS:Cell¡BNature¥H¤ÎScience¡C
¡u¥|¤jÂå¾Ç³»¥Z¡v¡G·s^®æÄõÂå¾ÇÂø»x(NEJM)¡B¬h¸¤M(Lancet)¡B¬ü°êÂå¾Ç·|Âø»x(JAMA)¥H¤Î^°êÂå¾Ç´Á¥Z(BMJ)¡C
1.2023.4.21-¯ØÅ¦ªº¯×ªÕÅÜ¡G¯ØÅ¦¾Çªº¼ï¦·©ÔÅ]²°
www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00064-X/abstract
2.2024.2.7-¤ñ¯×ªÕ¨x§óÄY«ªº¯×ªÕ¯Ø¡Iwww.edh.tw/article/25090
¯×ªÕ¯Ø¬OÃöÁ䨤¦â
¯Ø®q¯À¬O¥Ñ¯Ø¸¢ªºBeta²ÓM©Ò¤Àªc¡A¦Ó¯×ªÕ¹ï¯Ø¸¢¬O¦³¬r©Êªº¡C¬ã¨sµo²{¡A¦³¨Ç¤H¦b¯Ø¸¢¯×ªÕ§t¶q¶W¹L5¢Hªº®ÉÔ¡A´N±w¦³
¤G«¬¿}§¿¯f¤F¡C [¯×ªÕ¨x] ¥[¤W[¯×ªÕ¯Ø]´N¬O³y¦¨¿}§¿¯fµLªk±±¨îªº¨â¤jì¦]¡A¤]ºÙ¬°[Âù´`Àô²z½×¡C]
---------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2023/8/30 ¤U¤È 05:53:57²Ä 3431 ½g¦^À³
1.¸É¤W¤T´â½©¿}Áý¾i¨S±w¤W1«¬¿}§¿¯f¡¨ªºPÈ: 35%(P=0.021)¡A50%(P=0.012)¡C(°ª§C¿@«×ªºP<0.05¦³²Îp¤WÅãµÛ®t²§)
2.§ïµ½¯×ªÕ¯Ø¤Þ°_ªº¯Ø¯fÅÜ¡B[¿}§¿¯f] ©Î¨ä¥L¬ÛÃö¯f¯g¤§²Õ¦Xª«¤Î¤èªk±M§Q (SNP-6ÃĪ«)
¦h°µÂI¥\½Ò¼W±j²´¥ú¡A³zµø©Ò§ë¸ê¤½¥qªº¸¬Äª¸Ì½æªº¬O¬Æ»òÃÄ?¿ï¾Ü¦³¼ç¤Oªº¤½¥q¡A´N¥i¥H´£°ª³Ó²v!
¤£nªÈµ²©ó²{¦b¡A®æ§½©ñ¤j¤@ÂI¡A¦A©¹«e¬Ý·Q¹³¤@¦~«á¡B¤¦~«á¡A¤@¤Á³£·|Åܱo¤£¤@¼Ë¡C
----------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/9/11 ¤W¤È 08:01:05²Ä 2430 ½g¦^À³
¸¨¤«¤U¥Û??? §Ú¦b¹j¤é1/6°ê¹©ªÑ»ù¿ÄÂ_®É¦Ñ¦Äµ¥Ü!!!(°ê¹©¤G´ÁPȵS¥¼ª¾?)
¡u¤½µL´çªe¡A¤½³º´çªe¡C¼Zªe¦Ó¦º¡A·í©`¤½¦ó¡I¡v
----------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2022/4/8 ¤U¤È 07:50:51²Ä 1878 ½g¦^À³
...¤µ¤Ñ±q¸Ñª¼¼Æ¾Ú¨Ó¬Ý [¥h¦~ªº¥[¦¬«¯gªÌ] ´N¬O[»´¤¤¯g¦³®Ä©Ê«Ü¤£©úÅã¡A©Ò¥H¥[¤J«¯g±wªÌÁ{§É]
---------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2021/12/29 ¤U¤È 01:47:04²Ä 1534 ½g¦^À³
...°ê¹©:DMC«ØÄ³¼W¥[¦¬ªv»Ýn®ñ®ð¤ä«ù¤§«¯g¦í°|¯f±w¡C
³o®É¦³2ºØ¥i¯à©Ê:¤@¬O¦³®Ä©Ò¥H¥[¤J«¯g±wªÌ¡A¤G¬O¥i¯à»´¤¤¯g¦³®Ä©Ê¤£©úÅã¡A©Ò¥H¥[¤J«¯g±wªÌÁ{§É¬Ý¬Ý¡C
J&J»PGSKªº°ª¼h¬OÄø³J?¥H«e¹C»¡°ê·|ijûªý¼¸FDA¡A²{¦b¤£ª¾¹D¤Ï¹L¨Ó§Q¥Î³o±ø¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n???¬°½T«OOTCÃÄ«~ªº[¦w¥þ©Ê]¡A FDA¥u»Ý¤@¯È¦æ¬F©R¥O...
-------------------------------------------------------------------------------------------------
2023.7.28www.gao.gov/assets/gao-23-106570.pdf
¬ü°êFDA[«D³B¤èÃÄ]¤¤±Æ¥L©Ê±ø´Ú(¥«³õ¿W¦ûÅv)
...2018 ¦~1 ¤ë¼gµ¹°ê·|»â¾É¤Hªº¤@«Ê«H¤¤¡A¤@Ó¥Nªí®ø¶OªÌ§Q¯qªº²Õ´¤½¶}´£¥X¤F³o¼Ëªº¾á¼~¡G«D³B¤èÃĤ½¥q¥i¯à·|¨î¸û¦Ñ¦ý¦P¼Ë¦³®Äªº«D³B¤èÃĪº¨ÑÀ³¡A±q¦Ó¢¨Ï®ø¶OªÌÁʶR¸û·s¡B¸û¶Q¥BÀò±o[¿W®a¸gÀçÅv]ªºÃĪ«
Ó¤Hµ²½×:¤jÃļt©ñ±ó[¿W®a¸gÀçÅv]? ©ñ±ó±q®ø¶OªÌ¤f³U±Ç§ó¦h¿ú?
¤jÃļt·|«ç¼Ëª¾ªkª±ªk¡A¥HOTC±M½×q³æ½Ð¨D¦J÷ÅýFDAµo¥¬¦æ¬F©R¥O.....???? ³o¬OµL¨x¬rSNP-810ªºOTC«D³B¤èÃÄ»ùÈ¡I
...§ï²ªk®×¤º¤å¦³¹ªÀy«D³B¤èÃÄ[¦w¥þ³Ð·s]!
--------------------------------------------------------------------------------------------------
ªYÄ£ªº¥Ø¼Ð¬O´Â¦V¥H°ª¨x¦w¥þ©Êªº¤AñQÓi×ô¡u¨ú¥N¡v²{¦³¤AñQÓi×ôªº¥«³õ¡C
Ãļt¥i¥Hn¨DFDA§ó§ï¨Ï¥Î±ø¥ó©Î¦¨¤À.....µ¥--->´£¥æ(OTC±M½×q³æ½Ð¨DOMOR¡^
sbiaevents.com/files2024/OMUFA-Webinar-June-2024-Slides.pdf
¹ï©ó·s¼W©Î¥[±j¥H¤U [¦w¥þ¬ÛÃö] «D³B¤èÃıMµÛÅܧó¡AµL½×µ¥¯Å¬°¦ó¡AOMOR §¡¤£¦¬¨ú¥ô¦ó¶O¥Î(¨ä¾lÅܧón¦¬¿ú)¡G
¸T§Ò¯g¡Bĵ§i©Î¹w¨¾±¹¬I
Ãö©ó¨Ï¥Î©ÎÀݥάÛÃöªº·ÀIªºÁn©ú
¦³Ãö¾¯¶q©Mµ¹ÃĪº»¡©ú¡A¦®¦b´£°ª«D³B¤èÃıMµÛÃĪ«ªº¦w¥þ¨Ï¥Î
Ó¤Hµ²½×:´Á«Ý¹Ú¹Ò¦¨¯u¡A¥@¬É¦]¹Ú¦Ó§ïÅÜ!
...Ãļt§ä¥Á¥N¬IÀ£FDA-[¥P©é¥P]À¸½Xµ²§ô!
2024.6.14-¬ü°ê×§ï«áªº«D³B¤èÃıMµÛp¹ºÅܧó±q¹ï¤AñQ®ò°ò×ô¥Ö½§¤ÏÀ³Äµ§i¶}©l
¤µ¤Ñ¡AFDA µo¥¬¤F¤@¶µÀÀijªº[¦æ¬F©R¥O]....
--------------------------------------------------------------------------------------------------
Ãļt¥i¥Hn¨DFDA§ó§ï¨Ï¥Î±ø¥ó©Î¦¨¤À.....µ¥--->´£¥æ(OTC±M½×q³æ½Ð¨DOMOR¡^
FDAn¨DÃļt¥[µùĵ§i»y.....µ¥--->¥Îªº¬O(¦æ¬F©R¥O)
39¤À30¬í:¤À§O¦V¨äFDA»PEMA±N¨ä¾Ö¦³¨x¬r©Ê......²¾¥X¥«³õ....
Ó¤Hµ²½×:¤jÃļtªºª¾ªkª±ªk¡A§ó¥i©È!!!
----------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/7 ¤U¤È 08:31:15²Ä 3782 ½g¦^À³
ªYÄ£±N¥Ó½Ð¦w¥þ·sÃij\¥iÃÒ(¥«³õ±MÀçÅv?)¨Ã´£¨Ñµ¹°ê»Ú¤jÃļt(°ê»Ú¤jÃļt¤£¥Î«·s°µÁ{§É¥Ó½ÐÃÄÃÒ)
3.[FDA...¦æ¬F©R¥O±Â¤©[¥«³õ±MÀçÅv][¥«³õ±MÀçÅv][¥«³õ±MÀçÅv]
...OTCÃÄ«~§ï² (SNP-810¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i×§ï©Î§R°£FDA¨x¬rĵ»y¡C¥i×§ï©Î§R°£FDA¨x¬rĵ»y)
1.³Ì²×¦æ¬F©R¥Oµo¥¬«á¡AFDA ¥i¥H§ó§ï¶Ü¡H
¦³¤@¶µ±ø´Ú¤¹³\ FDA ¦b¦³·sÃÒ¾Úªí©ú¯S©wÃĪ«©Î¬YÃþÃĪ«ºc¦¨[¤£¨}¨Æ¥ó]ªº[¤£¦X²z·]ÀI¨Ã»Ýn¼ÐÅҩΨä¥LÃþ«¬ªº§ó§ï
®É¡A¤¹³\FDA ¹ï¥ô¦ó³Ì²×¦æ¬F©R¥O¶i¦æ§ó§ï¡C
2.»s³y°Ó¦p¦ó½Ð¨D§ó§ï±M½×¡H
»s³y°Ó¥i¥Hn¨D§ó§ï¨Ï¥Î±ø¥ó©Î¦¨¤À¡A¨Ò¦p³z¹L´£¥æ OTC ±M½×q³æ½Ð¨D¡]¡uOMOR¡v¡^¡C
3.¦b·sªº«D³B¤èÃĺʺޮج[¤U¡A§Úªº«D³B¤èÃĦ³¸ê®æÀò±o¯S³\¸gÀçÅv¶Ü¡H
¦pªG·sªº¤HÅé¬ã¨s¹ïµo¥¬³Ì²×¦æ¬F©R¥O¦ÜÃö«n¡A¨º»òFDA ¥i¥H¦bµo¥¬¥Ñ¥Ó¿ìªÌµo°_ªº°w¹ï·s«D³B¤èÃĬ¡©Ê¦¨¤À¡]¤§«e¥¼
¦C¤J¦U½×©Î©R¥O¡^ªº³Ì²×¦æ¬F©R¥O©Î°w¹ï¤£¦P¨Ï¥Î±ø¥óªº¦æ¬F©R¥O«á±Â¤©¥«³õ±MÀçÅv¡C
¯u¹ê.°È¹ê.¥¹ê
°ªº¯³zÀ£[¥ÌÅS¾J]«á¦å¼ß[¹[¿@«×]¤É°ª¬O¥Ñ©ó[K+¹[]±q²ÓM [²¾¥X] ¶i¤J²ÓM¥~²G...
--------------------------------------------------------------------------------------
1.2016.9.14(Nature¥D¥Z)¸~½F·LÀô¹Ò¤¤ªºÂ÷¤l§K¬Ì§í¨î¨î¤F T ²ÓM®ÄÀ³¥\¯à
www.nature.com/articles/nature19364
¸~½F¤ºT²ÓMªº±þÀù¬¡©Ê©¹©¹·|¨ü¨ì¼vÅT¡A¾ÉP¯e¯f¶i®i¡C§ÚÌ¥ý«eµo²{¡A¸~½F¤º²ÓM [¥~] K+ ªº¤É°ª»P¥¿¦b¶i¦æªº²ÓM¦º¤`¦³Ãö¡A³o¨î¤F CD8+ T ²ÓMªº Akt-mTOR °T¸¹¶Ç¾É©M®ÄÀ³¥\¯à¡C¬°¤F½w¸Ñ K+ ¤¶¾Éªº T ²ÓM§í¨î¡A§Ú̳z¹L°ò¦]¤â¬q¨Ó°§C²ÓM[¤º]K+¡C
2.2019.3.29-¸~½F¤¤ªºT²ÓM·F©Ê©M¥\¯à»Ùê¬O¥Ñ¦@¦P¾÷¨îIJµoªº
www.science.org/doi/full/10.1126/science.aau0135
§Ú̵o²{¸~½F·LÀô¹Ò¤¤¹L¶qªº [¹[]¬O³oºØ [¤G¤Àªk] ªº°ò¦¡A¦b«O«ù·F©Êªº¦P®ÉIJµo T ²ÓM®ÄÀ³¥\¯àªº§í¨î¡C°ª¤ô¥ªº²ÓM [¥~] ¹[³z¹L¨îÀç¾i§l¦¬¨Ó¨îT ²ÓM®ÄÀ³µ{§Ç¡A±q¦Ó»¤¾É¦Û¾½§@¥Î¨Ã´î¤Ö®ÄÀ³¾¹©M¯ÓºÜ¦ìÂIªº²Õ³J¥Õ¤AñQ¤Æ¡A
¶i¦Ó²£¥Í¨ã¦³§ïµ½ªºÅ餺«ù¤[©Ê¡B¦h¯à©Ê©M¸~½F²M°£¯à¤OªºCD8 + T ²ÓM¡C
¶i¦Ó²£¥Í¨ã¦³§ïµ½ªºÅ餺«ù¤[©Ê¡B¦h¯à©Ê©M¸~½F²M°£¯à¤OªºCD8 + T ²ÓM¡C
³oºØ¾÷¨îª¾ÃѼW¶i¤F§Ú̹ï T ²ÓM¥\¯à»Ùꪺ²z¸Ñ¡A¨Ã¥i¯à±a¨Ó·sªº¤èªk¡A±q¦Ó¯à°÷¶}¾v¥Î©óÀù¯g§K¬ÌªvÀøªº¼W±j T ²ÓMµ¦²¤¡C
1.2023.10.9-¡m¦ÛµM§K¬Ì¾Ç¡n¡G¬¥®á¤j¾Ç¹Î¶¤µo²{±Mªù½Õ¸`¸~½F¤¤T²ÓM¯ÓºÜªº¯S®í³J¥Õ¡I
www.nature.com/articles/s41590-023-01614-x
¬ã¨s´¦¥Ü¡ANFAT5ªº°ªªí²{¯à°÷¥[¼@¸~½F®û¼íCD8+T²ÓMªº¯ÓºÜ¡A©Î¥i§@¬°¼ç¦bªº§K¬ÌªvÀø¹vÂI¡A³z¹L¤¶¤JNFAT5ªº[ªí¹F©Î
¬¡©Ê]¨Ó´£°ªCD8+T²ÓM¹ï¸~½Fªº¤ÏÀ³¡A±q¦Ó§ïµ½Àù¯gªvÀøªº®ÄªG¡C
NFAT5ªº¬¡¤Æ¨ü²ÓM¥~ [º¯³zÀ£½Õ±±]
NFAT5ªº¬¡¤Æ¨ü²ÓM¥~ [º¯³zÀ£½Õ±±]
NFAT5ªº¬¡¤Æ¨ü²ÓM¥~ [º¯³zÀ£½Õ±±]
......NFAT5¹ï©ó¨ä¥¦¨ë¿E±ø¥ó¡A¦p®ñ¤ÆÀ£¤O¡B¯Ê®ñ¡B²ÓM¿E¯À¡B¨ë¿E¤£±Ó·P¡C
2.2013.7.19-¬¡©Ê®ñ½Õ¸` NFAT5 ¼Ð¹v°ò¦]ªºÀô¹Ò¨Ì¿à©Ê§í¨î www.nature.com/articles/emm201361
[°ªº¯³zÀ£] ¥ÌÅS¾J]¾¯¶q¨Ì¿à©Ê»¤¾É NFAT5 ¬¡©Ê¡A¦ý´î¤Ö LPS »¤¾Éªº IL-6 ²£¥Í¡C
3.2016.7.28-¾AÀ³©Ê§K¬Ì¨t²Î¦b¨x·l¶Ë©M¨x²ÓMÀùµo®i¤¤ªºÂù«§@¥Î
www.cell.com/cancer-cell/fulltext/S1535-6108(16)30269-0?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1535610816302690%3Fshowall%3Dtrue
CD8 +²ÓMªº¬¡¤ÆÅãµÛ«P¶i¨xÀùªºµo¥Í¡C CD8 +²ÓM¯ÓºÜªº¤p¹«ÀH«á§¡¥¼¥X²{¨x¸~½F
§Ú̪º¼Æ¾Ú½T©w CD8 + T ²ÓM¬Oµoª¢¬ÛÃö¨xÀùµo¥ÍªºÃöÁä²ÓM¦¨¤À¡C
------------------------------------------------------------------------------------------------
·|û¡GROGER588910148151 µoªí®É¶¡:2024/6/24 ¤U¤È 05:31:04²Ä 3847 ½g¦^À³
1. 2023.3.15-Nature¥D¥Z-¿¯¹²¢¨ý¾¯[¤T´â½©¿}]¬O[T²ÓM]¤¶¾É¤ÏÀ³ªºt½Õ¸`¾¯
¤T´â½©¿}Åã²{§í¨îCD4+ CD8+ T ²ÓM¼W´Þªº¾¯¶q¨Ì¿à©Ê¯à¤O
¡e°OªÌ·¨°ê¤å¡þ¥x¥_³ø¾É¡f³Ò°Ê³¡³Ò°Ê°òª÷¹B¥Î§½°ê¤º§ë¸ê²Õ«e²Õªø´å°i¤å¡A³Q±±©ó¥ô¤º»P®É¥ôÄ_¨Î¶°¹Î°õ¦æªøð·¡¯Pµ¥¤H¦X§@¡A¾Þ±±³Ò°Ê°òª÷¡A°ª»ù©Ó±µÄ_¨Î¶°¹Î¡u˳f¡v¥X²æªº18¸U±i»·ªF¦Ê³fªÑ²¼¡A¨ÏÄ_¨ÎÀò§Q¬ù4.5»õ¤¸¡A¤@¼f¨Ì¶¡±µ¾ÞÁaªÑ»ù¸o«§P´å°i¤å9¦~¡B𷡯P8¦~....
-------------------------------------------------------------------------------------------------
¬ÝµÛ·ÀY»¡¸Ü¡A¤jªÑªF¤£§C½Õ? ¨S±ÂÅv«e·Q¦³¬ßÀY¡A¬Ýú³°Ó·Q³y¶Õ§_?
[¨Ï¥Î¤H¼Æ³Ì¦h]ªºÃĪ«¬O¦¨¤À¬°¤AñQ®ò×ôªº¤îµhÃÄ¡A¨Ï¥Î¤H¼Æ¹F898¸U¤H¡A±Æ¦W²Ä¤@
2017.9.14-¬ü°ê°ê·|¼f¬d«D³B¤èÃÄ ¨âÄҥߪk¯ó®×±N¹ý©³§ï² FDA ¹ï«D³B¤è²£«~ªººÊºÞ¤è¦¡(¦]¬°¤¾ªøªk³Wµ{§Ç¡AFDA ªá¤F¤C¦~®É¶¡¤~n¨D¹ï¤AñQÓi×ôµo¥X¨xŦ¬r©Êĵ§i)
----------------------------------------------------------------------------------------------
¤T¶¥¬q³W«h¨î©w¬yµ{¡]ANPR¡BTFM ©M FM¡^¤¾ªøªk³Wµ{§Ç-->FDA ªá¤F¤C¦~®É¶¡¤~n¨D¹ï¤AñQÓi×ôµo¥X¨xŦ¬r©Êĵ§i)
2024¦~6¤ë14¤é¤@¯È[¦æ¬F©R¥O]--->[«D³B¤èÃÄ]±MµÛp¹ºÅܧó±q¹ï¤AñQ®ò°ò×ô [¥Ö½§¤ÏÀ³]ĵ§i¶}©l¡C
§ñÃö¦w¥þ©Êªº¨x¬r¦p¦ó¸Ñ??????
We could start with the skin reactions to acetaminophen.
(§ÚÌ¥i¥H±q¹ï¤AñQ®ò°ò×ôªº¥Ö½§¤ÏÀ³¶}©l)
2.2020.3.27-¤t´¶Ã±¸p¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n¥´³qFDA¥ô·þ¤G¯ß!!!
¤T¶¥¬q³W«h¨î©w¬yµ{¡]ANPR¡BTFM ©M FM¡^±N³Q¦æ¬F©R¥O¬yµ{¨ú¥N¡C
3.2024.6.14-¬ü°ê×§ï«áªº[«D³B¤èÃÄ]±MµÛp¹ºÅܧó±q¹ï¤AñQ®ò°ò×ô [¥Ö½§¤ÏÀ³]ĵ§i¶}©l
-------------------------------------------------------------------------------------------------
µL¨x¬r¹ï¤AñQ®ò°ò×ô²Å¦X¤Þ¥Î3.³o±øªk³W???
3.¦b [·sªº«D³B¤èÃÄ] ºÊºÞ®Ø¬[¤U¡A§Úªº«D³B¤èÃĦ³¸ê®æÀò±o¯S³\¸gÀçÅv¶Ü¡H
¦pªG [·sªº¤HÅé¬ã¨s] ¹ïµo¥¬ [³Ì²×¦æ¬F©R¥O] ¦ÜÃö«n¡A¨º»òFDA ¥i¥H¦bµo¥¬¥Ñ¥Ó¿ìªÌµo°_ªº°w¹ï·s«D³B¤èÃĬ¡©Ê¦¨¤À¡]¤§«e¥¼¦C¤J¦U½×©Î©R¥O¡^ªº³Ì²×¦æ¬F©R¥O©Î°w¹ï¤£¦P¨Ï¥Î±ø¥óªº¦æ¬F©R¥O«á±Â¤© [¥«³õ±MÀçÅv]¡C
Ãļt¸òFDA [¥P©é¥P]À¸½Xµ²§ô!
2017.09.13 ²{¥N¤ÆFDAªk³W«D³B¤èÃĪ« FDAÃĪ«µû¦ô»P¬ã¨s¤¤¤ß¡]CDER ¡^¥D¥ôJanet Woodcock¦b²³Ä³°|³Æ¸ß¸ê®Æ
www.govinfo.gov/content/pkg/CHRG-115hhrg27228/html/CHRG-115hhrg27228.htm
...Dr. Woodcock. OK. Well, we could start with the skin reactions to acetaminophen.
-------------------------------------------------------------------------------------------------
Ãļt§ä¥Á¥N¬IÀ£FDA-[¥P©é¥P]À¸½Xµ²§ô!
2024.6.14-¬ü°ê×§ï«áªº«D³B¤èÃıMµÛp¹ºÅܧó±q¹ï¤AñQ®ò°ò×ô¥Ö½§¤ÏÀ³Äµ§i¶}©l
www.fda.gov/drugs/drug-safety-and-availability/fda-issues-agency-initiated-proposed-order-regarding-otc-monograph-drugs-containing-acetaminophen
¤µ¤Ñ¡AFDA µo¥¬¤F¤@¶µÀÀijªº[¦æ¬F©R¥O]¡A¥H¸Ñ¨M»P§t¦³¹ï¤AñQ®ò°ò×ôªº«D³B¤è (OTC) ±MµÛÃÄ«~¬ÛÃöªº¦w¥þ°ÝÃD¡C
...FDA ÃĪ«µû¦ô»P¬ã¨s¤¤¤ß«D³B¤èÃĿ줽«Ç¥D¥ô Theresa Michele Âå¾Ç³Õ¤hªí¥Ü¡G¡§¤µ¤Ñªº¦æ°Ê¥Nªí¤F FDA ¹ê¬I°ê·|·s±ÂÅv¡]§@¬° OTC ±M½×§ï²ªº¤@³¡¤À¡^ªº«n¨½µ{¸O¡C¡¨ ¡§¤µ¤Ñ´£¥Xªº©R¥O¦³§U©ó½T«O§ÚÌ¥«³õ¤W«D³B¤èÃĪº¦w¥þ©Ê©M¦³®Ä©Ê¡C¡¨
---------------------------------------------------------------------------------------------
¹L¥hªº¤Q¦~......¥L̪º¤èªk¦b¦Ñ¹«¡B½Þ©Mª¯¨¤W°ö¨|·sªº°g§A¨xŦ-->8¦¨¾÷²v¦b¤HÅ餺ªø¥X·sªº°g§A¨xŦ!
±µ¨ü¨x²ÓM²¾´ÓªÌ²×¥Í»ÝnªA¥Î§K¬Ì§í¨î¾¯(´N¹³±µ¨ü²¾´Ó¾¹©xªÌªA¥Î§Ü±Æ¥¸ÃĪ«¤@¼Ë)-->³oÂI·¥¤j¨î¤F¾A¥Î±wªÌ!